Financial Data and Key Metrics Changes - The company reported revenue of approximately $4 million for Q1 2025, a decrease from $10 million in the same quarter of 2024, primarily due to a shift in focus towards internal and co-development programs [22][23] - The net loss for the quarter was roughly $46 million, compared to a loss of around $41 million in Q1 2024, resulting in a loss of CAD0.15 per share [24][25] - The company ended the quarter with approximately $630 million in cash and equivalents, along with $180 million in available committed government funding, totaling about $810 million in liquidity [21][27] Business Line Data and Key Metrics Changes - The company maintained a cumulative total of 16 molecules that have reached the clinic, with no new molecules advancing in the quarter [22] - The company initiated work on one partner-initiated program, bringing the cumulative total to 97 programs with downstream participation [21] Market Data and Key Metrics Changes - The market opportunity for ABCL635, targeting vasomotor symptoms associated with menopause, is estimated to exceed $2 billion in annual sales, with approximately 30% of women experiencing moderate to severe symptoms [9][10] Company Strategy and Development Direction - The company is focused on advancing its lead programs, ABCL635 and ABCL575, into clinical trials, with plans to complete the CTA process for both programs [18][19] - The company aims to transition from a platform company to a clinical-stage biotech, with over 20 internal and co-development programs in the pipeline [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the biology and differentiation of ABCL635, highlighting the unmet medical need for non-hormonal treatments for vasomotor symptoms [18] - The company plans to start Phase I studies for ABCL635 in Q3 2025, with key readouts expected in mid-2026 [18] Other Important Information - The company is investing in building clinical manufacturing capabilities, expected to be operational by the end of 2025 [27] - The company has received commitments for funding from the Government of Canada's Strategic Innovation Fund and the Government of British Columbia, which will support its GMP facility and internal pipeline advancement [27] Q&A Session Summary Question: What do you expect this asset needs to see in terms of Phase one data to capture a competitive edge? - Management indicated that they will look for safety data and important biomarker data, which will provide early signs of target engagement and efficacy [30][31] Question: What should we expect to see from the upcoming ABCL575 preclinical data? - Management stated that the preclinical data will include early animal work and PK analysis, with expectations for a superior dosing regimen [35] Question: Given the risk around translatability of NKTR engagement, is there a precedent that gives confidence? - Management noted preclinical data from nonhuman primates provides optimism, but emphasized caution in drug development [37][38] Question: How are you thinking about the next development candidates? - Management is looking for high conviction biology with large unmet medical needs and compelling differentiation, likely focusing on GPCR or ion channel targets [40][41] Question: Can you provide context on the pause of Novorok molecules in the clinic? - Management believes the pause is related to fundraising efforts by Novorok, which is common in the current environment [57] Question: Is there consideration for U.S.-based manufacturing redundancies? - Management confirmed that their current manufacturing facility in Canada supports their clinical trials, and they have not yet considered U.S.-based manufacturing [58][59]

Clinical Development Programs - ABCL635 Phase 1 clinical trials are expected to initiate in Q3 2025[9, 36] - ABCL575 Phase 1 clinical trials are expected to initiate in Q3 2025[4, 36] - ABCL635 is a potential first-in-class antibody for the non-hormonal treatment of vasomotor symptoms (hot flashes)[6] - Phase 1 Readout safety & early efficacy of ABCL635 is anticipated in the first half of 2026[11, 34] Financial Status - The company has approximately $810 million in available liquidity to execute on its strategy[5, 44] - The company has approximately $630 million in total cash, cash equivalents, and marketable securities[45] - The company has approximately $180 million in total available government funding[43] - Q1 2025 revenue was $42.5 million, an increase of $3.2 million compared to $39.3 million in Q1 2024[50] - Q1 2025 net loss was $46 million, equivalent to ($0.15) per share[52] Market Opportunity - Approximately 40 million women are of menopausal age in the US[11, 15] - Approximately 30% of women experience moderate-to-severe VMS[11, 15]

Financial Performance - Total revenue for Q1 2025 was $4,235,000, a decrease of 57.5% compared to $9,954,000 in Q1 2024[13] - Net loss for Q1 2025 was $45,621,000, compared to a net loss of $40,610,000 in Q1 2024, indicating a 12.4% increase in losses[13] - The company reported a comprehensive loss of $48,241,000 for Q1 2025, compared to a comprehensive loss of $40,706,000 in Q1 2024, representing a 18.5% increase[13] - Operating expenses for Q1 2025 were $66,895,000, up from $64,848,000 in Q1 2024, indicating a rise of 3.2%[79] - Interest income decreased by $2.4 million, or 23%, from $(10.40) million in Q1 2024 to $(8.05) million in Q1 2025, primarily due to lower cash balances and interest yields[93] - The company reported a net loss of $162.9 million for the year ended December 31, 2024, compared to a net loss of $146.4 million for 2023[115] - Accumulated earnings as of December 31, 2024, were $116.9 million, down from $279.8 million in 2023[115] Assets and Liabilities - Total assets decreased from $1,360,553,000 as of December 31, 2024, to $1,344,208,000 as of March 31, 2025, a decline of 1.2%[12] - Total liabilities increased from $304,469,000 to $321,226,000, marking a rise of 5.5%[12] - Shareholders' equity decreased from $1,056,084,000 to $1,022,982,000, a decline of 3.1%[12] - Cash and cash equivalents increased from $156,325,000 at the end of 2024 to $159,266,000 by March 31, 2025, reflecting a growth of 1.2%[12] - Total current assets rose from $751,370,000 to $764,978,000, an increase of 1.8%[12] Research and Development - Research and development expenses increased to $42,496,000 in Q1 2025, up from $39,287,000 in Q1 2024, representing a 5.5% increase[13] - Significant investments are expected in research and development to enhance antibody discovery and development capabilities[75] - The company is focused on developing first-in-class and best-in-class antibody-based medicines for high unmet medical needs[67] - The company has invested significantly in research and development efforts to enhance its technology and platform, but these investments carry inherent risks that may affect operating results[141] - The company has not expensed any amounts related to research and development milestone payments during the three months ended March 31, 2024, or March 31, 2025[51] Government Contributions - The company received a total of CAD $300 million ($222.3 million) in multi-year contributions from the Government of Canada and the Government of British Columbia to develop and manufacture antibody medicines[53] - Government Contribution 1 includes CAD $175.6 million ($125.6 million) for R&D related to COVID-19, with CAD $116.9 million ($88.5 million) repayable based on revenue thresholds[52] - The company has recorded CAD $83.1 million ($60.4 million) in respect of Government Contribution 2 from the Government of Canada as of March 31, 2025[54] - The company has a deferred government contribution of $164.4 million as of March 31, 2025, compared to $157.6 million as of December 31, 2024[57] Clinical Development and Trials - Cumulative total of 16 molecules advanced into the clinic as of March 31, 2025, an increase of 23% from 13 molecules in the previous year[82] - The company plans to start Phase 1 clinical trials in Canada for two AbCellera-led programs in the second half of 2025[73] - The company has initiated a total of 97 partner-initiated programs with downstream participation, reflecting an 8% increase from 90 programs[82] - The company’s ability to generate revenue is dependent on the success of its antibody discovery and development capabilities[129] - The successful development of product candidates is uncertain, with a high failure rate in clinical studies, which could adversely affect business and operating results[177] Market and Regulatory Challenges - The company faces challenges in obtaining adequate reimbursement for its products, which is crucial for market acceptance and revenue generation[192] - The Medicare Modernization Act and the Inflation Reduction Act have introduced pricing pressures and regulatory changes that could impact the pharmaceutical industry[194] - Regulatory approval for product candidates is subject to various factors, including government budget and funding levels, which could delay or prevent timely commercialization[176] - The company may experience delays in patient enrollment for clinical trials, which is critical for timely completion and regulatory approval[168] - Changes in regulatory requirements may necessitate amendments to clinical trial protocols, potentially affecting costs and timelines[162] Liquidity and Future Outlook - The company believes it has sufficient liquidity from existing cash and cash equivalents to meet its working capital needs for at least the next 36 months[123] - Future funding requirements will depend on various factors, including the introduction of new technologies and costs related to litigation[124] - The company anticipates continued losses for the foreseeable future and cannot predict when it may achieve profitability[115] - The company acknowledges that interim, preliminary, or top-line data from clinical trials may change as more patient data become available, which could significantly impact business prospects[173] Miscellaneous - The company is in an ongoing patent infringement litigation against Bruker, with a jury trial scheduled for January 2026[111] - The company has completed the implementation of the consolidated financial accounting module of its new ERP system, which is expected to enhance financial reporting accuracy[107] - The company is currently implementing changes to its internal controls over financial reporting due to the new ERP system[108] - The company does not have any product candidates approved for sale in any jurisdiction, limiting its ability to realize full market potential[186]

Financial Performance - Total revenue for Q1 2025 was $4.2 million, a decrease from $10.0 million in Q1 2024[7] - Net loss for Q1 2025 was $45.6 million, compared to a net loss of $40.6 million in Q1 2024, resulting in a loss per share of $(0.15)[7][16] - Net loss for the three months ended March 31, 2024, was $40,610, compared to a net loss of $45,621 for the same period in 2025[19] Expenses - Research and Development (R&D) expenses increased to $42.5 million in Q1 2025 from $39.3 million in Q1 2024, reflecting a 5.5% growth in investments[7][16] - Sales and Marketing (S&M) expenses decreased to $2.8 million in Q1 2025 from $3.4 million in Q1 2024[7] - General & Administrative (G&A) expenses decreased to $16.2 million in Q1 2025 from $17.4 million in Q1 2024[7] - Cash used in operating activities was $41,708 for the three months ended March 31, 2024, significantly higher than $11,554 in 2025[19] - Stock-based compensation was $17,409 for the three months ended March 31, 2024, down from $14,786 in 2025[19] Liquidity and Cash Flow - The company ended Q1 2025 with over $800 million in available liquidity, including $633 million in cash and cash equivalents[2][7] - Cash and cash equivalents and restricted cash at the end of the period were $150,862 for March 31, 2024, compared to $186,556 for the same date in 2025[19] - Total cash, cash equivalents, and restricted cash shown on the balance sheet was $148,572 for March 31, 2024, versus $184,266 for the same date in 2025[19] - Net cash provided by investing activities was $29,910 for the three months ended March 31, 2024, compared to $7,935 in 2025[19] Operational Highlights - Cumulative partner-initiated program starts with downstreams reached 97 in Q1 2025, an 8% increase from 90 in Q1 2024[4] - The number of molecules that have reached the clinic increased to 16, representing a 23% growth from 13 in Q1 2024[4] - The company anticipates starting Phase 1 clinical trials for ABCL635 and ABCL575 in the second half of 2025[2] - AbCellera is focused on advancing its internal pipeline of first-in-class and best-in-class programs while collaborating on innovative drug development with partners[8] Changes in Financial Metrics - Purchases of property and equipment amounted to $24,140 for the three months ended March 31, 2024, compared to $10,636 in 2025[19] - Proceeds from marketable securities were $306,545 for the three months ended March 31, 2024, compared to $190,027 in 2025[19] - Research fees and grants receivable showed a significant change of $(18,576) for the three months ended March 31, 2024, compared to $(1,133) in 2025[19] - Deferred revenue changed by $(8,017) for the three months ended March 31, 2024, while it increased by $13,313 in 2025[19]

Summary of AbCellera Biologics (ABCL) 2025 Conference Call Company Overview - **Company**: AbCellera Biologics (ABCL) - **Location**: Vancouver, Canada - **Focus**: Therapeutic antibody development - **Public Listing**: Nasdaq since 2020, initial share price at $20, currently trading around $2.5 [4][3] Key Points and Arguments 1. **Biotech Industry Context**: The biotech sector is experiencing significant challenges, with many companies facing volatile market conditions. AbCellera considers itself fortunate compared to others in the industry [4][5]. 2. **Leadership**: The company is led by Carl Hansen, a visionary CEO, who emphasizes the importance of drug development and its impact on human life [5][6]. 3. **Historical Perspective**: The company draws parallels between current biotech advancements and historical moments in physics, suggesting that the industry is at a pivotal point for innovation [7][8][9]. 4. **Drug Development Challenges**: Drug development is described as a Herculean task, with high costs, lengthy timelines, and low success rates. Only a small number of companies have successfully developed sustainable drug pipelines [11][12]. 5. **Company Aspirations**: AbCellera aims to be among the few companies that can develop and sustain a successful drug pipeline, particularly in the Canadian biotech landscape, which lacks major pharmaceutical companies [13][14]. 6. **Therapeutic Focus**: The company is focused on developing therapeutic antibodies, having completed over 100 programs for partners, with 16 molecules reaching phase one clinical trials [15][17]. 7. **COVID-19 Contributions**: AbCellera's COVID-19 antibodies treated over 2.5 million patients, saving numerous lives and hospitalizations [18]. 8. **Pipeline Development**: The company is transitioning to wholly owning its drug candidates, with significant investments in infrastructure, including a GMP manufacturing facility expected to be operational for clinical batches in 2026 [19][20][21]. 9. **Financial Position**: AbCellera has approximately $650 million in cash and $200 million in committed capital from government sources, providing a strong financial foundation for drug development [21]. 10. **Target Selection Criteria**: The company employs a rigorous framework for selecting drug targets, focusing on validated biology, commercial opportunity, differentiation, and clear clinical development plans [22][23]. 11. **Upcoming Clinical Trials**: Two molecules, ABCL-635 and ABCL-575, are set to enter clinical trials, with the first target being disclosed during the earnings call [24][25][26]. 12. **Market Potential**: The total addressable market for ABCL-635 is estimated to exceed $2 billion, indicating potential blockbuster status [27]. 13. **Differentiation Strategy**: For ABCL-575, differentiation is expected based on half-life and dosing frequency compared to competitors [28][29]. Additional Important Content - **Strategic Partnerships**: The company maintains strategic partnerships with major pharmaceutical firms, which have not been negatively impacted by its focus on internal programs [37][39]. - **T Cell Engagement**: AbCellera is developing a portfolio for T cell engagement, which has attracted interest from partners like AbbVie [38]. - **Manufacturing Plans**: The company plans to manufacture its own antibodies, particularly those it has discovered, rather than operating strictly as a contract manufacturer [42]. This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting AbCellera's position within the biotech industry and its future plans for drug development.

Financial Data and Key Metrics Changes - The company reported a revenue of almost $29 million for the year, a decrease from approximately $38 million in 2023, primarily due to a shift towards internal and co-development programs [37] - Research and development expenses were approximately $167 million, down $8 million from the previous year, reflecting a one-time payment of about $32 million made in 2023 [38] - The net loss for the year was roughly $163 million, compared to a loss of about $146 million the previous year, which included non-cash impairment charges for in-process R&D of approximately $47 million [39] Business Line Data and Key Metrics Changes - The company has a cumulative total of 96 partner-initiated programs with downstream participation, with 14 programs still actively led or co-led by the company [30][33] - The company initiated two new partnerships in the first half of 2024 and expanded one existing collaboration, while also reducing new discovery partnership activities [25][9] Market Data and Key Metrics Changes - The company is focusing on the therapeutic areas of oncology, neurology, and immunology, which reflect the broader industry activity [35] - The total addressable market for the lead program ABCL635 is estimated to be at least $2 billion in annual sales, while the atopic dermatitis market for ABCL575 is already over $10 billion [17][20] Company Strategy and Development Direction - The company is transitioning from a platform and partnership model to a clinical-stage biotech, with a focus on building an internal pipeline and reducing new discovery partnerships [7][61] - The strategic focus includes selecting programs based on unmet needs, commercial opportunities, differentiation, and clear development paths [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's liquidity position, with over $800 million available to execute its strategy [10][43] - The company plans to initiate Phase 1 clinical trials for its lead programs in 2025 and expects to complete its transition to a clinical-stage biotech [27][24] Other Important Information - The company has completed its move to a new headquarters and is on track to bring its clinical manufacturing facility online in 2025 [9] - The company has received commitments for funding from the Government of Canada's Strategic Innovation Fund and the government of British Columbia, which will support its GMP facility and internal pipeline advancements [42] Q&A Session Summary Question: What competencies are needed for clinical trials across multiple disease areas? - Management stated that they are building up translational science and clinical development teams to support their first two programs moving into clinical development [47][48] Question: Is there a finite number of candidates under the AbbVie collaboration? - Management confirmed that they are excited about the collaboration and are working on multiple but a small number of targets [54] Question: What is the attrition rate for partner-initiated programs? - Management indicated that the attrition rate is consistent with expectations, with over half of the programs still progressing after being handed back to partners [60] Question: Why reduce the number of partnerships pursued? - Management explained that the transition to a clinical-stage biotech necessitated a focus on internal programs, while still seeking opportunities in TCE collaborations [62] Question: What preparations are being made for the upcoming CTA filings? - Management confirmed that extensive preparations have been made for both programs, with no noteworthy special considerations at this time [83]

Company Performance - AbCellera Biologics Inc. reported a quarterly loss of $0.11 per share, better than the Zacks Consensus Estimate of a loss of $0.15, and an improvement from a loss of $0.17 per share a year ago, representing an earnings surprise of 26.67% [1] - The company posted revenues of $5.05 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 40.83%, and down from $9.18 million in the same quarter last year [2] - Over the last four quarters, AbCellera has surpassed consensus EPS estimates three times but has not beaten consensus revenue estimates [2] Stock Outlook - The immediate price movement of AbCellera's stock will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $13.97 million, and for the current fiscal year, it is -$0.71 on revenues of $46.43 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which AbCellera belongs, is currently in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact AbCellera's stock performance [5][6]

Financial Data and Key Metrics Changes - AbCellera reported a revenue of approximately $29 million for the year, a decrease from about $38 million in 2023, primarily due to a shift towards internal and co-development programs [23][24] - The company experienced a net loss of roughly $163 million for the year, compared to a loss of about $146 million the previous year, which included non-cash impairment charges for in-process R&D of approximately $47 million [24][25] - Cash and equivalents at year-end were over $650 million, with total available liquidity estimated at approximately $840 million, including committed government funding [18][27] Business Line Data and Key Metrics Changes - The company advanced two programs, ABCL-635 and ABCL-575, which are positioned for CTA filings in Q2 2025 [7][17] - AbCellera has a cumulative total of 96 partner-initiated programs with downstream participation, with 16 molecules having reached the clinic [19][20] - The internal pipeline has grown to 27 programs, up from 19 at the beginning of the year, indicating a focus on internal development [21][22] Market Data and Key Metrics Changes - The total addressable market for ABCL-635 is estimated at $2 billion in annual sales, while the market for atopic dermatitis, relevant to ABCL-575, exceeds $10 billion [10][12] - The company is focusing on oncology, neurology, and immunology, reflecting broader industry activity [21] Company Strategy and Development Direction - The company is transitioning from a platform and partnership model to a clinical-stage biotech, emphasizing internal pipeline development and clinical trials [6][17] - Strategic focus includes initiating Phase 1 clinical trials for lead programs, nominating additional development candidates, and completing platform investments [17] - The company aims to build a portfolio of wholly owned and co-owned drug development programs, assessing opportunities based on scientific conviction, unmet needs, differentiation, and development paths [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's liquidity and ability to fund operations for the next three years while advancing the pipeline [27] - The competitive landscape, particularly from China, is being monitored, but management believes their portfolio is robust against such dynamics [35] - The company is optimistic about the upcoming clinical trials and the potential for significant advancements in their drug development programs [60] Other Important Information - The company is reducing new discovery partnership activities while still seeking collaborations in specific areas, such as TCE platforms [16] - The new clinical manufacturing facility is expected to come online by the end of 2025, supporting the company's growth strategy [26] Q&A Session Summary Question: What competencies are needed for clinical trials across different disease areas? - Management highlighted the importance of building translational science and clinical development teams to support diverse programs, with hiring focused on development and clinical areas as programs progress [30][32] Question: What is the status of the AbbVie collaboration? - The collaboration with AbbVie is seen as a significant step forward, with a focus on a small number of targets and a commitment to advancing TCE science [34][48] Question: What is the attrition rate for partner-initiated programs? - Management indicated that details on attrition rates will be disclosed in future filings, with expectations of consistent progress among partnered programs [38][39] Question: Why reduce the number of partnerships? - The decision to transition to a clinical-stage biotech necessitated a focus on internal programs, while still seeking strategic partnerships that align with their objectives [40][41] Question: What preparations are being made for the upcoming CTA filings? - Preparations for the CTA filings for ABCL-635 and ABCL-575 have been extensive, with clinical teams and plans in place to ensure smooth execution [60]

Investment and Financials - The company has invested over $600 million in building its infrastructure and expanding capabilities since its incorporation in 2012[33]. - The company has generated over $100 million in cumulative earnings since 2012 and has approximately $840 million in available liquidity as of December 31, 2024[33]. - The company secured CAD $300 million ($222.3 million) in non-dilutive financing in May 2023 to build new capabilities for developing and manufacturing antibody medicines[57]. - The company expects to incur losses and negative operating cash flow in the near-to-medium term due to ongoing investments in its pipeline[112]. - The company has a long-term capital allocation strategy, focusing on building intellectual capital and infrastructure to support future drug development[113]. Research and Development - Approximately 40% of the total research and development spend in 2024 is allocated to platform development, enhancing capabilities for future drug discovery[56]. - The company is advancing a pipeline of more than 20 internal discovery programs across multiple modalities and indications[26]. - The company aims to reduce the time from target nomination to IND filing to two years or less through ongoing investments in integrated target-to-clinic capabilities[154]. - The company has developed its T-cell-engager platform and initiated internal programs targeting eight important tumor targets, alongside 10 internal programs focused on GPCRs and ion channels[139]. - The company’s investments in technology development are aimed at increasing the probability of success for its drug development programs, particularly in high unmet medical need areas[151]. Clinical Trials and Drug Development - The company expects to submit Clinical Trial Applications for its internal programs ABCL635 and ABCL575 in Q2 2025[26]. - ABCL635, targeting metabolic and endocrine conditions, is anticipated to enter clinical trial authorization (CTA) submission in Q2 2025, with a potential market exceeding $2 billion in annual sales[62]. - ABCL575, a monoclonal antibody for atopic dermatitis, is also expected to submit a CTA in Q2 2025, leveraging a clinically validated mechanism to modulate inflammation[63][64]. - The company advanced two drug programs, ABCL635 and ABCL575, into IND/CTA-enabling studies in 2023, with plans for clinical trial authorizations in 2025[61]. - The company plans to start its first clinical trial in 2025, which will require compliance with numerous regulations in the life sciences sector[217]. Partnerships and Collaborations - The company has established multiple partnership agreements with pharmaceutical and biotechnology companies, including Eli Lilly and Company for multi-target, multi-year projects in immunology and neuroscience, announced on July 31, 2024[93]. - Total potential milestone payments from partnership agreements amount to $8.69 billion, with $5.51 billion expected from commercial milestones[97]. - The company has initiated 96 partner-initiated programs as of December 31, 2024, which could yield milestone and royalty payments[92]. - The company has successfully completed the agreed scope of work for 76 out of 96 partner-initiated programs, with 51 programs actively progressing[143]. - The company earned over $950 million in combined royalties from commercial sales of COVID-19 antibody assets developed in partnership with Lilly from 2020 to 2022[138]. Market and Competitive Landscape - The biotechnology sector is projected to be a significant growth opportunity, with global therapeutic antibody sales nearing $300 billion in 2023 and expected to exceed $450 billion by 2028, reflecting a CAGR of over 10%[80]. - The therapeutic antibody market is characterized by a significant number of blockbuster drugs, with around 50 achieving annual sales exceeding $1 billion in 2023[80]. - Over 50% of new-drug approvals in the U.S. from 2011 to 2021 originated from smaller biotechnology companies with annual revenues below $500 million, indicating a competitive landscape[101]. - The company faces competition from various sources, including large pharmaceutical companies and specialized biotechnology firms, in the antibody therapeutics market[106]. - The company aims to unlock new market segments and improve discovery speed, estimating that accelerating the path to market by one year could enhance the value of an average approved treatment by over $100 million[88]. Workforce and Employee Engagement - The voluntary turnover rate for the company was 4.7% in 2024, indicating strong employee engagement and retention[77]. - The company employs a workforce comprising approximately 62% scientists, 14% engineers and data scientists, and 24% business professionals, with over 54% holding advanced degrees[75]. Intellectual Property and Patents - The company has developed an expansive patent portfolio with over 100 issued or allowed patents and over 70 pending applications worldwide as of December 31, 2024[172]. - The company utilizes various forms of intellectual property protection, including trademarks, copyrights, and trade secrets, to safeguard its proprietary rights[173]. - The company acquired Trianni, including all existing intellectual property and issued patents related to the Trianni mouse, with patents expected to expire in July 2031[196][197]. - The Trianni intellectual property portfolio includes 14 issued patents in various jurisdictions, focusing on transgenic animals and methods of use[197]. - The company has a patent family directed to enhanced production of immunoglobulins, which includes six issued patents and four pending applications, with expiration expected in February 2037[198]. Regulatory Compliance - The company is subject to various regulations governing clinical studies and commercial sales, impacting its ability to develop and sell therapeutic products[219]. - The company is subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, which could impact its operations and interactions in the healthcare sector[222]. - The company maintains compliance with environmental laws, which govern the handling and disposal of hazardous substances used in its operations[221].

Financial Performance - Total revenue for FY 2024 was $28.8 million, a decrease of 24.2% from $38.0 million in 2023[8] - Net loss for FY 2024 was $162.9 million, compared to a net loss of $146.4 million in 2023, representing a 11.1% increase in losses[4] - Revenue for Q4 2024 was $5.1 million, representing 18% of total revenue for the year[8] - The net loss for Q4 2024 was $34.2 million, or $(0.12) per share[9] - Net earnings for December 31, 2023, showed a loss of $146,398, compared to a profit of $158,519 in 2022, indicating a significant decline in profitability[24] Expenses - Research and Development (R&D) expenses for FY 2024 were $167.3 million, down 4.3% from $175.7 million in 2023[8] - General & Administrative (G&A) expenses increased to $72.7 million in FY 2024, up 18.0% from $61.0 million in 2023[8] - The company reported a significant increase in amortization and impairment of intangible assets, rising to $78,312 in 2024 from $11,637 in 2023[24] - Stock-based compensation increased to $64,183 in 2023, up from $49,481 in 2022, reflecting a rise of approximately 30%[24] Cash Flow and Liquidity - The company ended FY 2024 with approximately $840 million in total available liquidity, including $652.9 million in cash and cash equivalents[8] - Cash flows from operating activities decreased to $(43,877) for the year ending December 31, 2023, down from $277,360 in 2022[24] - Total cash and cash equivalents at the end of the period decreased to $160,610 in 2023 from $414,650 in 2022, reflecting a decline of approximately 61%[24] - Cash flows from investing activities showed a net outflow of $(221,108) in 2023, compared to $(352,625) in 2022, indicating a reduction in investment spending[24] - The total cash, cash equivalents, and restricted cash shown on the balance sheet decreased to $158,320 in 2023 from $411,535 in 2022, a decline of approximately 62%[24] Clinical Development - Cumulative partner-initiated program starts with downstreams increased to 96 in 2024, up 10% from 87 in 2023[5] - The number of molecules in the clinic rose to 16, reflecting a 23% increase from 13 in 2023[5] - AbCellera plans to initiate Phase 1 clinical trials for its first two programs, ABCL635 and ABCL575, in 2025[2] Other Financial Metrics - The company experienced a decrease in net cash provided by financing activities, which rose to $10,356 in 2023 from $(1,628) in 2022[24] - Research fee and grant receivable increased significantly, with a decline of $(45,933) in 2023 compared to $(22,715) in 2022[24] - The company reported a cash outflow of $(763,982) for the purchase of marketable securities in 2022, which increased to $(1,021,510) in 2023[24]